Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEMLUVIO vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nemolizumab is a humanized monoclonal antibody that binds to the interleukin-31 receptor alpha (IL-31RA), blocking IL-31 signaling. IL-31 is a cytokine involved in pruritus, inflammation, and barrier dysfunction in atopic dermatitis and other conditions.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Treatment of pruritus associated with atopic dermatitis in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies.
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
2 mg orally once daily.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
The terminal elimination half-life is approximately 40 hours (range 35-50 hours), supporting once-daily dosing for sustained therapeutic effect.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Nemolizumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal elimination via biliary excretion accounts for approximately 60%; the remainder is metabolized and excreted as metabolites.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
99.5% bound to plasma proteins, primarily albumin.
Approximately 85-90% bound to serum albumin.
Volume of distribution is 0.45 L/kg, indicating distribution primarily into extracellular fluid and limited tissue penetration.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral bioavailability is 75% under fasting conditions; administration with a high-fat meal reduces bioavailability to approximately 60%.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
Not recommended if e GFR <15 m L/min/1.73 m². No adjustment for e GFR ≥15.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: no adjustment; Child-Pugh B or C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Not established for patients <18 years.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment; use caution due to potential renal impairment.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
None.
None.
Hypersensitivity reactions including anaphylaxis have been reported.,Eczema herpeticum (Kaposi's varicelliform eruption) has been observed in clinical trials.,Potential increased risk of serious infections (e.g., parasitic infections) due to IL-31 inhibition.,Prior to initiation, patients should be evaluated for helminth infections and treated if infected.,Monitor for signs and symptoms of hypersensitivity reactions during and after administration.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
History of hypersensitivity to nemolizumab or any excipients in the formulation.,Clinically significant helminth infection (e.g., parasitic worm infection) until treatment and resolution of infection.
Hypersensitivity to AURLUMYN or any of its components.
Avoid grapefruit and grapefruit juice as they may increase NEMLUVIO levels. High-fat meals may delay absorption but do not affect overall exposure. Limit caffeine intake as it may exacerbate side effects.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
NEMLUVIO (narlaprevir) is contraindicated in pregnancy due to observed fetal toxicity in animal studies. In rats and rabbits, maternal exposure at 0.2–0.5 times the human exposure (AUC) resulted in increased fetal resorptions, reduced fetal body weight, and skeletal abnormalities including misshapen sternebrae and delayed ossification. No human data are available; however, the drug's mechanism (inhibition of viral protease) and animal findings indicate a high risk of teratogenicity (FDA Pregnancy Category X). First trimester exposure carries the highest risk of major malformations. Second and third trimester exposure may cause fetal growth restriction and potential neurodevelopmental effects.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No data exist on the presence of narlaprevir in human milk, its effects on the breastfed infant, or its effects on milk production. In lactating rats, narlaprevir was excreted in milk at concentrations similar to maternal plasma (milk-to-plasma ratio approximately 1.0). Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during NEMLUVIO therapy and for 7 days after the last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
NEMLUVIO is contraindicated in pregnancy; therefore, no dose adjustment is recommended. If a pregnant woman inadvertently receives the drug, discontinue immediately; pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may lead to subtherapeutic concentrations, but no dosing guidance can be provided due to the contraindication. Use in pregnant patients is not appropriate under any circumstances.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
NEMLUVIO is a selective norepinephrine reuptake inhibitor indicated for fibromyalgia. Monitor for blood pressure elevation; titrate dose slowly to minimize adverse effects. Discontinue gradually to avoid withdrawal syndrome. Use with caution in patients with cardiovascular disease or recent myocardial infarction.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take NEMLUVIO exactly as prescribed, usually once daily with or without food.,Avoid driving or operating heavy machinery until you know how this medication affects you, as it may cause dizziness or somnolence.,Do not stop taking NEMLUVIO abruptly, as this may cause withdrawal symptoms such as headache, nausea, or insomnia.,Notify your healthcare provider if you experience rapid heart rate, chest pain, or severe headache.,Limit alcohol intake while on NEMLUVIO as it may increase risk of liver injury or worsen side effects.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEMLUVIO vs AURLUMYN, answered by our medical review team.
NEMLUVIO is a Antineoplastic Agent that works by Nemolizumab is a humanized monoclonal antibody that binds to the interleukin-31 receptor alpha (IL-31RA), blocking IL-31 signaling. IL-31 is a cytokine involved in pruritus, inflammation, and barrier dysfunction in atopic dermatitis and other conditions.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEMLUVIO and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEMLUVIO is: 2 mg orally once daily.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEMLUVIO and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEMLUVIO is classified as Category C. NEMLUVIO (narlaprevir) is contraindicated in pregnancy due to observed fetal toxicity in animal studies. In rats and rabbits, maternal exposure at 0.2–0.5 times the human exposure . AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.